Propanc Biopharma, Inc. (PPCB)
PPCB moved a median of 0.00% 30 minutes after news, and -1.63% by the close. How PPCB actually reacts to news — the realized, point-in-time move the market made, measured across 144 labeled events over the last three years with zero look-ahead.
PPCB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 36% | 121 |
| 30-min | 0.00% | 41% | 129 |
| 60-min | 0.00% | 36% | 129 |
| to close | -1.63% | 29% | 133 |
| Middle 50% of PPCB reactions | -3.33% to +2.36% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 144 |
Half of all Propanc Biopharma, Inc. news events land between -3.33% and +2.36% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when PPCB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PPCB's baseline. Nothing else.
Recent PPCB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells | Press release | GlobeNewswire | -2.11% | -2.42% | |
| Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer | Press release | GlobeNewswire | -0.61% | -14.54% | |
| Form PRE 14C Propanc Biopharma, Inc. For: Oct 08 | SEC filing · Form PRE | SEC EDGAR | +0.00% | -2.00% | |
| Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib | Press release | GlobeNewswire | -4.65% | -0.06% | |
| Form S-1 Propanc Biopharma, Inc. | SEC filing · Form S-1 | SEC EDGAR | +2.07% | +1.72% | |
| Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results | Press release | GlobeNewswire | -1.46% | -0.52% | |
| Form 10-K Propanc Biopharma, Inc. For: Jun 30 | SEC filing · Form 10-K | SEC EDGAR | -2.28% | -13.27% | |
| Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015 | Press release | GlobeNewswire | +1.47% | +0.63% | |
| Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc. | Press release | GlobeNewswire | +0.82% | -25.12% | |
| Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027 | Press release | GlobeNewswire | +0.00% | -1.98% | |
| Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit | Press release | GlobeNewswire | -0.00% | -36.47% | |
| Form DEF 14C Propanc Biopharma, Inc. For: Aug 20 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -3.57% | |
| Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP | Press release | GlobeNewswire | +3.52% | +3.57% | |
| Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers | Press release | GlobeNewswire | -4.07% | -1.63% | |
| Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models | Press release | GlobeNewswire | -4.00% | +8.80% | |
| Form PRE 14C Propanc Biopharma, Inc. For: Aug 04 | SEC filing · Form PRE | SEC EDGAR | +8.16% | +20.41% | |
| Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program | Press release | GlobeNewswire | +8.16% | +20.41% | |
| Form EFFECT Propanc Biopharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -7.63% | |
| Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal | Press release | GlobeNewswire | — | -3.50% | |
| Form S-1 Propanc Biopharma, Inc. | SEC filing · Form S-1 | SEC EDGAR | -0.67% | -8.00% | |
| Form 8-K Propanc Biopharma, Inc. For: Jul 08 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.62% | |
| Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd | Press release | GlobeNewswire | -11.47% | -5.21% | |
| Propanc Biopharma Initiates $5.0 Million Share Repurchase Program | Press release | GlobeNewswire | -5.25% | -11.50% | |
| Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study | Press release | GlobeNewswire | -1.38% | -11.47% | |
| Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program | Press release | GlobeNewswire | +37.42% | -23.59% | |
| Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain | Press release | GlobeNewswire | +0.00% | -0.56% | |
| Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade | Press release | GlobeNewswire | +1.03% | -9.28% | |
| Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients | Press release | GlobeNewswire | -5.05% | +1.26% | |
| Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results | Press release | GlobeNewswire | +1.53% | -5.56% | |
| Form 10-Q Propanc Biopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.53% | -5.56% | |
| Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans | Press release | GlobeNewswire | +0.13% | -7.47% | |
| Form EFFECT Propanc Biopharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -2.96% | -9.52% | |
| Form S-1 Propanc Biopharma, Inc. | SEC filing · Form S-1 | SEC EDGAR | -5.34% | -1.94% | |
| Form DEF 14C Propanc Biopharma, Inc. For: Mar 31 | SEC filing · Form DEF | SEC EDGAR | — | +2.12% | |
| Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain | Press release | GlobeNewswire | -6.07% | -7.67% | |
| Form PRE 14C Propanc Biopharma, Inc. For: Mar 19 | SEC filing · Form PRE | SEC EDGAR | +1.01% | -0.08% | |
| Form PRE 14A Propanc Biopharma, Inc. For: Mar 19 | SEC filing · Form PRE | SEC EDGAR | +1.01% | -0.08% | |
| Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy | Press release | GlobeNewswire | +3.96% | -7.77% | |
| Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study | Press release | GlobeNewswire | -1.13% | -13.85% | |
| Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models | Press release | GlobeNewswire | -8.40% | -6.95% | |
| Form 8-K Propanc Biopharma, Inc. For: Feb 20 | SEC filing · Form 8-K | SEC EDGAR | +2.14% | +0.89% | |
| Form EFFECT Propanc Biopharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +1.76% | -4.05% | |
| Form S-1/A Propanc Biopharma, Inc. | SEC filing · Form S-1 | SEC EDGAR | -5.18% | -4.53% | |
| Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results | Press release | GlobeNewswire | -1.72% | -12.13% | |
| Form 10-Q Propanc Biopharma, Inc. For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | -6.82% | -0.04% | |
| Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market | Press release | GlobeNewswire | -7.74% | -2.27% | |
| Form S-1 Propanc Biopharma, Inc. | SEC filing · Form S-1 | SEC EDGAR | -1.44% | -0.90% | |
| Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations | Press release | GlobeNewswire | +2.61% | +2.13% | |
| Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia | Press release | GlobeNewswire | +1.47% | -0.40% | |
| Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer | Press release | GlobeNewswire | -3.22% | -19.80% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PPCB section they belong to.
Where else PPCB is measured.
PPCB earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Mustang Bio, Inc. (MBIO) | 144 | -0.46% | 41% |
| Patterson Companies, Inc. (PDCO) | 144 | 0.00% | 48% |
| Cara Therapeutics, Inc. (CARA) | 143 | -0.56% | 46% |
| Nutriband Inc. (NTRB) | 143 | 0.00% | 44% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Propanc Biopharma, Inc.'s median reaction calculated?
Every labeled PPCB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 144 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of PPCB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PPCB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.